Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US9750728B2 · kind B2 · utility
0Cited by
28References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 22, 2016 |
| Grant date | Sep 5, 2017 |
| Priority date | — |
| Expiry date | Nov 22, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a patient in need of treatment for a disease selected from the group consisting of cancer, hamartoma syndrome and hereditary myopathy, the method comprising administering to the patient an effective dose of at least one PRCP and PREP dual antagonist pyridine compound of Formula (I) or an acid salt thereof, which can be administered either alone or in combination with at least one mTOR inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.